ArticleJournal of oncology2012
Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.
Article in Journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?Asian Pacific journal of cancer prevention : APJCP · 2021Pooled it
- Coexistence of Medullary Thyroid Carcinoma and Bilateral Pheochromocytoma in MEN2A Syndrome: Atypical Presentation and Clinical Insights From a Case Report.Clinical case reports · 2026Article
- Biogenic amine testing in the South African public health care system.Practical laboratory medicine · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Dissecting a diagnostic enigma: Hypertension in a young patient from an organ of Zuckerkandl paraganglioma.Clinical case reports · 2023Article
- Management of SHDB positive patient with metastatic bilateral giant retroperitoneal paragangliomas.Urology case reports · 2022Article
- Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data.Cancers · 2021Article
- Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion.Discover oncology · 2021Article
- Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.Journal of endocrinological investigation · 2021Review
- Identification of MicroRNA-Related Tumorigenesis Variants and Genes in the Cancer Genome Atlas (TCGA) Data.Genes · 2020Article
- Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE).Journal of the Endocrine Society · 2020Article
- Texture analysis of routine T2 weighted fat-saturated images can identify head and neck paragangliomas - A pilot study.European journal of radiology open · 2020Article
- The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions.Frontiers in behavioral neuroscience · 2020Review
- Diagnosis and treatment of a diaphragmatic pheochromocytoma: A case report.International journal of surgery case reports · 2020Article
- Expression of PDK1 in malignant pheochromocytoma as a new promising potential therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.Virchows Archiv : an international journal of pathology · 2019Article
- Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2019Review
- Therapies targeting the signal pathways of pheochromocytoma and paraganglioma.OncoTargets and therapy · 2019Article
- [Therapeutic management of malignant paragangliomas: an illustrative case and literature review].The Pan African medical journal · 2019Review
- Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.Endocrine pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pheochromocytomas/paragangliomas are rare tumors with a poor prognosis. Malignancy is diagnosed by the development of metastases as evidenced by recurrences in sites normally devoid of chromaffin tissue. Histopathological, biochemical, molecular and genetic markers offer only information on potential risk of metastatic spread. Large size, extraadrenal location, dopamine secretion, SDHB mutations, a PASS score higher than 6, a high Ki-67 index are indexes for potential malignancy. Metastases can be present at first diagnosis or occur years after primary surgery. Measurement of plasma and/or urinary metanephrine, normetanephrine and metoxytyramine are recommended for biochemical diagnosis. Anatomical and functional imaging using different radionuclides are necessary for localization of tumor and metastases. Metastatic pheochromocytomas/paragangliomas is incurable. When possible, surgical debulking of primary tumor is recommended as well as surgical or radiosurgical removal of metastases. I-131-MIBG radiotherapy is the treatment of choice although results are limited. Chemotherapy is reserved to more advanced disease stages. Recent genetic studies have highlighted the main pathways involved in pheochromocytomas/paragangliomas pathogenesis thus suggesting the use of targeted therapy which, nevertheless, has still to be validated. Large cooperative studies on tissue specimens and clinical trials in large cohorts of patients are necessary to achieve better therapeutic tools and improve patient prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.